Top

European Journal of Medical Research

Published in:

Open Access 01-12-2016 | Case report

Long term disease free survival with multimodal therapy in small cell bladder cancer

Authors: Isabel Heidegger, Gennadi Tulchiner, Georg Schäfer, Wolfgang Horninger, Renate Pichler

Published in: European Journal of Medical Research | Issue 1/2016

Abstract

Background

Small cell bladder cancer (SCBC) is an aggressive subtype accounting for less than 1 % of all bladder malignancies associated with rapid progression, early metastases formation and high mortality rates.

Case presentation

We present an unusual long term disease free survival of a 60 year-old man who was diagnosed with SCBC two and a half years ago. He underwent four cycles of cisplatin/etoposide chemotherapy as well as a prophylactic whole-brain radiotherapy followed by a radical cystoprostatectomy and ileal neobladder with extended pelvic lymphadenectomy. Since 33 months the patient is now recurrence-free.

Conclusion

In this case report, we were able to show that early multimodal therapy results in long term disease free survival, thus we highly recommend neoadjuvant chemotherapy as a part of multimodal management of a primary metastases-free, localized and surgically resectable SCBC.

Blomjous CE, Vos W, De Voogt HJ, et al. Small cell carcinoma of the urinary bladder. A clinicopathologic, morphometric, immunohistochemical, and ultrastructural study of 18 cases. Cancer. 1989;64:1347–57.CrossRefPubMed

Lopez JI, Angulo JC, Flores N, Toledo JD. Small cell carcinoma of the urinary bladder. A clinicopathological study of six cases. Br J Urol. 1994;73:43–9.CrossRefPubMed

Mazzucchelli R, Scarpelli M, Galosi AB, Lopez-Beltran A, Cheng L, Montironi R. “Pathology of the Bladder” (Capitolo di Libro Internazionale), p. 26–39, October 2015, in Advances in Bladder Cancer Management, Copyright © 2015 Future Medicine Ltd, doi: 10.2217/9781780844237, eISBN (PDF): 978-1-78084-423.

Williamson SR, Zhang S, Yao JL, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol. 2011;24(8):1120–7.CrossRefPubMedPubMedCentral

Wang X, Zhang S, MacLennan GT, et al. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res. 2007;13(3):953–7.CrossRefPubMed

Geynisman DM, Handorf E, Wong YN, et al. Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer Med. 2016;5(2):192–9. doi:10.1002/cam4.577 Epub 2015 Dec 18.CrossRefPubMed

Moretto P, Wood L, Emmenegger U, et al. Management of small cell carcinoma of the bladder: consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). Can Urol Assoc J. 2013;7:E44–56.CrossRefPubMedPubMedCentral

Celik O, Ekin G, Ipekci T, et al. Diagnosis and treatment in primary bladder small cell carcinoma: literature review. Arch Ital Urol Androl. 2016;88(1):52–5.CrossRefPubMed

Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014;32:3801–9.CrossRefPubMedPubMedCentral

10.

Siefker-Radtke AO, Dinney CP, Abrahams NA, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the MD Anderson cancer experience. J Urol. 2004;172(2):481–4.CrossRefPubMed

11.

Siefker-Radtke AO, Kamat AM, Grossman HB, et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009;27(16):2592–7.CrossRefPubMedPubMedCentral

12.

Lynch SP, Shen Y, Kamat A, et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013;64(2):307–13.CrossRefPubMed

13.

Thota S, Kistangari G, Daw H, et al. A clinical review of small-cell carcinoma of the urinary bladder. Clin Genitourin Cancer. 2013;11(2):73–7.CrossRefPubMed

14.

Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo clinic experience. Cancer. 2005;103(6):1172–8.CrossRefPubMed

Title: Long term disease free survival with multimodal therapy in small cell bladder cancer
Authors: Isabel Heidegger
Gennadi Tulchiner
Georg Schäfer
Wolfgang Horninger
Renate Pichler
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 1/2016
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-016-0234-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Long term disease free survival with multimodal therapy in small cell bladder cancer

Abstract

Background

Case presentation

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2016

Hyaluronidase: from clinical applications to molecular and cellular mechanisms

Resuscitation with polymeric plasma substitutes is permissive for systemic inflammatory response syndrome and sepsis in multiply injured patients: a retrospective cohort study

Pseudoaneurysm of the anterior tibial artery after interlocking tibial nailing: an unexpected complication

Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists

Breast reconstruction after neoadjuvant radio chemotherapy: review and personal technique IDEAL concept

sMICA as novel and early predictors for acute myocardial infarction